Drug name(s)
Iberdomide Zenbexus™Indications and usage
Iberdomide is indicated in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Side effects needing medical attention
Most common adverse reactions in combination with daratumumab and hyaluronidase-fihj and dexamethasone are: upper respiratory tract infection, fatigue, musculoskeletal pain, pneumonia, diarrhea, motor dysfunction, rash, sleep disorder, hypogammaglobulinemia (low levels of immunoglobulins), COVID-19, and constipation.
The most common lab abnormalities are neutrophil count decreased, white blood cell count decreased, and lymphocyte count decreased.